

The role of smoking cessation in lung cancer patients

**Dimitrios Theofilos MD,
Charalampos Marketos MD,
Danai Bisirtzoglou MD, PhD,
Antigoni Sakelaropoulou MD,
Vasiliki Michalaki MD,
Athanasios Zetos MD,
George Politis MD, PhD**

Pneumology Department, "Saint Savvas"
Anticancer Hospital, Athens, Greece

Key words:

- Lung cancer
- Smoking cessation

Correspondence:

Dimitrios Theofilos, MD, MSc,
Pneumology Department, "Saint Savvas" Anticancer
Hospital, Athens
171 Alexandras Av., Athens 11522, Greece
E-mail: pneymoagsavvas@gmail.com

ABSTRACT

Lung cancer is the leading cause of death from cancer. The association of the disease with smoking is undeniable, and in the majority of cases the patients are active or former smokers. The continuation of smoking in patients with lung cancer reduces the survival and increases the risk of disease recurrence and second primary tumor incidence. Furthermore, it reduces the response to chemotherapy and or radiotherapy, delays the healing time of surgical wounds, increases the risk of postoperative complications and finally causes exacerbation of chronic diseases from which the patient may be suffering. As has been documented that smoking cessation has multiple and significant benefits for patients with lung cancer, the success of this goal in this specific patient population is a challenge. It seems that the diagnosis is a powerful incentive for patients to stop smoking, but many will require organized and systematic help. Health professionals should have an active role and education on smoking cessation methods. The opportunity to participate in smoking cessation programs should be offered to all patients and their relatives who wish to stop smoking. The treatment for smoking cessation including counseling, behavioral therapy, medication and regular monitoring, should be an integral part of treating patients with lung cancer.

Pneumon 2015, 28(4):333-339.

INTRODUCTION

Every year the new cases of lung cancer rises up to 1,800,000 and the deaths from the disease worldwide are 1,180,000. More than 210,000 new cases diagnosed in 2012 and 157,000 patients died in the US, while in Europe more than 400,000 new cases diagnosed. Lung cancer is now the leading cause of death by neoplasia since it is responsible for 20% of mortality among all cancers¹⁻⁵.

Cigarette smoking is responsible for 90% of lung cancer cases⁶. It is estimated that at the time of diagnosis, the prevalence of smoking is 24-60%,

and up to 83% of all smokers seem to continue smoking after diagnosis of lung cancer⁷⁻¹³. Although most patients want to quit, many of them cannot succeed¹⁴⁻¹⁶.

IS THERE A BENEFIT OF SMOKING CESSATION IN PATIENTS WITH LUNG CANCER;

A large number of studies suggest that smokers have a 20 times higher relative risk of suffering from lung cancer than non-smokers. It seems that this risk is mainly associated with the duration of exposure to tobacco products and daily cigarette consumption¹⁷. Cigarette smoke is irritating the pulmonary tissue and has been shown to influence lung function, as assessed by spirometry. Cigarette smoke contains almost 5000 chemicals, fifty of which are known carcinogens. The most important are polycyclic aromatic hydrocarbons and nitrosamines. These substances can bind to the DNA, thereby predisposing to the occurrence of mutations. Also according to recent data, nicotine is involved in development processes of cancer both by promoting angiogenesis and through direct effects on the control mechanisms of cell death and apoptosis¹⁸⁻²³. Quitting smoking has short and long term benefits for the smoker. The short term benefits include better control of blood pressure, improving oxygen transport, improve cardiorespiratory function and immune response as well as the restoration of smell and taste senses²⁴. Stop smoking is also associated with improved cognition, mental wellbeing and self-esteem that lead to an overall improved quality of life²⁵. Patients with lung cancer have the same benefits as other smokers from quitting so they can observe a decrease of fatigue and shortness of breath, increase physical activity and improve appetite, sleep, mood and their performance status^{26,27}. A reduction in mortality associated with other diseases related to smoking such as coronary heart disease, stroke and chronic obstructive pulmonary disease has also been observed^{28,29}.

Smoking cessation is associated with increased survival of patients with non-small cell lung cancer (NSCLC) at early stages. The results depend on the duration of cessation before the diagnosis³⁰. A recent study which examined the effect of smoking in the quality of life of patients with small cell lung cancer (SCLC) which survived at least 6 months after diagnosis confirmed the negative effect of smoking in the quality of life of these patients. Furthermore it was observed that smoking cessation even in time near the diagnosis can improve the quality of life and symptoms of patients³¹.

A 10 studies review with meta-analysis by Parsons et al found that the continuation of smoking in patients with early-stage NSCLC was associated with a significantly increased risk of disease recurrence and increased all-cause mortality, while in patients with SCLC with limited disease, the risk of disease relapse, the risk of second primary tumor growth and mortality were also increased in patients who continued smoking after diagnosis. Thus, patients who continued to smoke have twice the risk of death compared to those who stopped smoking. That fact was attributed mainly to the delay of the progression of cancer than to the prevention of cardiopulmonary diseases achieved with smoking cessation³².

SMOKING EFFECT IN POSTOPERATIVE COURSE OF PATIENTS WITH LUNG CANCER

Approximately 20% of patients who are about to undergo surgery for lung cancer continue to smoke in the immediate preoperative period and 30%-60% continue to smoke postoperatively³³. Smoking can adversely affect the postoperative course of patients undergoing lung cancer surgery, because of the increased risk of developing postoperative respiratory and cardiovascular complications compared to non and former smokers³⁴. Furthermore the healing of surgical wounds is delayed in smokers because both nicotine and carbon monoxide cause vasoconstriction, cell hypoxia and inhibition of tissue regeneration. It also increases the risk of infections and bronchopleural fistula, as well as the morbidity and mortality^{35,36}. Smoking was an independent predictor of morbidity in the first 30 postoperative days in patients who undergo pneumonectomy³⁷. In another study, smoking was found to be a predictor of prolonged hospitalization (>14 days) in patients who underwent lobectomy. Prolonged treatment was associated with more complications such as bronchoconstriction, need for re-intubation and aspiration in these patients compared to non-smokers^{38,39}.

A prospective study of Barrera et al with 300 patients who had undergone lung cancer surgery for primary or metastatic lung cancer, showed that non-smokers had significantly higher values of FEV1 and DLCO compared to smokers. The overall rate of postoperative complications, including pneumonia, was statistically significantly lower for non-smokers. They finally found that smoking history of more than 60 pack-years is an independent risk factor for respiratory complications after thoracotomy⁴⁰.

In another study the relationship between the period of preoperative abstinence and the occurrence of complications after surgery was investigated in 288 patients who underwent surgery for lung cancer. It was observed that the risk of respiratory complications decreased in patients who stopped smoking at least 4 weeks before surgery, while those who had quit for more than 10 weeks, had the same risk with non smokers. Smoking cessation was associated with fewer complications in patients who did not smoke for at least one month before surgery^{41,42}.

Gajdos et al retrospectively studied the effect of smoking on the occurrence of postoperative complications and mortality in patients undergoing surgery for cancer and the differences depended on the location of the primary cancer. It was observed that smokers had a higher incidence of pneumonia, difficulty in weaning from the ventilator, higher re-intubation rate compared to non-smokers, and higher mortality at first year. By directly comparing smokers and former smokers in the same patient group the existence of higher risk for postoperative complications and death in the first year was discovered for the smokers. Thus, the authors conclude that intervention for smoking cessation should be imposed before any surgery for cancer in order to reduce the risk of postoperative complications, prolonged hospitalization and risk of death⁴³.

Patients with lung cancer by stopping smoking early before surgery may have better postoperative course, so patients should be encouraged and assisted to stop smoking. The time that must elapse from smoking cessation to surgery to achieve the best results is not fully clarified. However, the surgery would be done promptly, even if the period of interruption is less than one month, since there is a risk of cancer progression^{44,45}.

Ebbert et al studied 4577 patients with SCLC and NSCLC, of which 11% were smokers, 58% were former smokers (had stopped smoking at least 6 months before diagnosis) and 31% were smokers (smoked every day or had stopped smoking for at less than six months at the diagnosis). The median survival for NSCLC patients was 1.4 years for non-smokers, 1.3 years for former smokers and 1.1 years for smokers ($p < 0,01$). In women patients who did not smoke greater improvement in survival was observed compared to men. In contrast, there were no differences in the survival of patients with SCLC⁴⁶.

In another multicenter study with 169 patients who underwent lung surgery for NSCLC the five-year survival was reduced in smokers than non- and former smokers. The difference in survival was statistically significant only among smokers and non-smokers ($P = 0,02$), suggesting

that the period of smoking cessation does not affect the long-term survival⁴⁷.

EFFECT OF SMOKING TO CHEMOTHERAPY AND RADIOTHERAPY RESPONSE, IN PATIENTS WITH LUNG CANCER

It has been shown that prolonged administration of nicotine in SCLC cell cultures, causes increased resistance to antineoplastic agents such as etoposide, cisplatin, mitomycin, and taxanes⁴⁸. Nicotine increases the metabolism of many drugs through induction of hepatic enzymes⁴⁹. Smoking affects the pharmacokinetics of erlotinib increasing clearance and decreasing plasma levels. Erlotinib, used in the treatment of NSCLC, is an inhibitor of tyrosine kinase epidermal growth factor receptor (EGFR) and it is metabolized by the liver. It has been hypothesized that induction of cytochrome P450 in the liver of smokers is responsible for increased drug clearance^{50,51}. Shepherd et al. found that twice the normal amount of erlotinib needs to be administered to smokers compared to non-smokers, to achieve the necessary level of plasma drug⁵².

Systemic therapy for lung cancer has a narrow therapeutic index such that small changes in plasma concentrations or exposure in smokers may result in suboptimal therapy and poor outcomes. However, prospective trials should take into consideration the effects of smoking history on drug pharmacokinetics and efficacy. The metabolizing enzyme phenotype in smokers may require individualized dose algorithms for specific agents⁵³.

Elevated levels of carbon monoxide (CO) found in smokers were associated with relative tissue hypoxia due to easier binding of CO to hemoglobin and leftward shift of the release curve of oxyhemoglobin. Tissue hypoxia in turn seems to cause decreased response to chemotherapy and radiotherapy⁵⁴.

It has further been found that smoking is a major risk factor for the development of radiation pneumonitis in patients with lung cancer who have been treated with radiotherapy⁵⁵. A higher rate of respiratory tract infections has also been observed in smokers undergoing radiotherapy for lung cancer, which was combined with reduced survival⁵⁶.

A study showed that among patients with early stage NSCLC, smokers had worse survival prognosis after radiotherapy. It has also been found that patients with small cell lung cancer who quit smoking before chemotherapy or radiotherapy, have higher response rates and longer

survival compared to those who have not ceased^{57,58}.

Despite the growing evidence that the existence of smoking cessation after diagnosis of lung cancer is associated with better treatment outcomes and better prognosis, the perception that smoking cessation in these patients does not offer substantial benefits remains⁵⁹. Survival rates in lung cancer are poor, about 7% for the five-year survival, while some patients are candidates for palliative treatment only. However, about 20% of patients are diagnosed early enough and could be cured. These patients have a relatively good prognosis with a five-year survival rate of 60%-75% and 36%-50% for NSCLC stages I and II respectively^{60,61}. When the prognosis of the primary tumor is favorable, then there is strong evidence that continued smoking increases the risk of a second primary tumor. Data indicate that cigarette smoking before first cancer diagnosis increases second cancer risk among cancer survivors, and elevated cancer risk in these survivors is likely due to increased smoking prevalence⁶². More specifically, in a study of patients with SCLC lung the risk of a second neoplasm, particularly NSCLC, was 3.5 to 4.4 times greater than in the general population. In those who continued smoking the risk was significantly higher, especially in those who had undergone radiotherapy and those who had received chemotherapy with alkylating agents while second primary lung cancer are rare in never-smokers⁶³. Additionally it was found that for patients who stopped smoking at the time of diagnosis the risk was greater than for those who had stopped 6 months before diagnosis⁶⁴. Smoking increases not only the first cancer but also a second or subsequent primary cancer. Moreover, the results from recent quitters versus current smokers suggest that smoking cessation may decrease the risk for subsequent primary cancer, especially for smoking-related subsequent primary cancers in cancer survivors⁶⁵.

As the survival of patients with lung cancer prolongs, the quality of life of these patients is becoming more important and a series of studies show that smoking cessation improves the quality of life. Therefore smoking cessation should be an integral part of treatment of these patients⁶⁶⁻⁶⁸.

THE DIAGNOSIS OF LUNG CANCER AS MOTIVATION FOR SMOKING CESSATION

Continued smoking after diagnosis of lung cancer reduces survival, increases the risk of relapse and the

risk of a second primary tumor, reduces the therapeutic effects and increases the complications of the disease and of the antineoplastic treatment⁶⁹⁻⁷³. However, a proportion of 13%-20% of patients with lung cancer continues to smoke after diagnosis^{74,75}.

In a study of patients with lung and head and neck cancer, the causes for which many patients avoid joining in smoking cessation programs were investigated. Those who did not participate were mainly the patients with head and neck cancer, those who had fewer respiratory symptoms, who smoked fewer cigarettes and felt less ready to quit smoking. A similar study showed that among smokers, the younger ones, those with early stage disease and those with a smoker partner were more interested to participate in smoking cessation programs. However finally, only 50% of smokers participated, although the majority of the patients were informed about such programs. We wish to emphasize the need for interventions in order to inform and motivate patients to increase their participation in smoking cessation programs^{76,77}. Although the diagnosis of lung cancer is a strong motivating factor for patients to quit smoking, it is not sufficient on its own and many patients will need additional support. Many are those who resumed smoking after tumor resection, usually in the first two months after surgery. Most susceptible are those who stop smoking for a shorter period before the surgery, and those who feel greater desire to smoke. Intervention for maintaining abstinence should begin immediately after surgery⁷⁸.

The combination of medication and behavioral therapy increases the success rates of smoking cessation⁷⁹. Strong prognostic value for the likelihood of recurrence of the smoker is living with smokers. Patients with lung cancer often live with a smoker and it is appropriate to extend the process of smoking cessation in/being partner and close family environment to achieve better results⁸⁰.

Physicians who care for lung cancer patients recognize the importance of tobacco cessation as a necessary part of clinical care, but many still do not provide assistance to their patients as a routine part of cancer care⁸¹.

Regarding the use of e-cigarettes for smoking cessation, the International Association for the Study of Lung Cancer (IASLC) advises against recommending their use at this time. There is absence of sufficient evidence that e-cigarettes are effective and safe for treating nicotine dependence in cancer patients. The IASLC does recommend that research be done to evaluate the safety and efficacy of e-cigarettes as a cessation treatment in cancer patients⁸².

CONCLUSIONS

A large number of patients with lung cancer are former smokers. Many of those who were diagnosed with lung cancer were current smokers and some of them continue to smoke after diagnosis, while others after a period of abstinence relapse and continue smoking.

Several investigators have ruled that smoking should be discontinued preoperatively in patients able to undergo lung surgery, as well as prior to chemotherapy or radiotherapy. There are several indications that continuing smoking after diagnosis of cancer reduces the survival period, increases the risk of recurrence and second primary tumor incidence, reduces the therapeutic effect, delays the time to healing of surgical wounds. Furthermore, patients who quit smoking have better quality of life.

Smoking cessation in these patients is a challenge. It has been observed that the diagnosis is a strong incentive to disrupt the patient from smoking, but not enough for everyone. The right time for intervention, the appropriate approach to achieve the best results is the subject of studies. Maybe early intervention, with active involvement and training of health professionals who cure these patients, would motivate them to participate massively in smoking cessation programs. The patients could play an active role to motivate their familiars to stop smoking but it remains to identify the most effective course of action. Information, encouragement and participation in such programs should be offered to all patients, but also to their relatives who want to stop smoking. The weaning from tobacco should be pursued in patients with lung cancer at all stages of the disease: diagnosis, treatment and monitoring.

The smoking cessation therapy including counseling, behavioral therapy, medication and regular monitoring should be an integral part of treating patients with lung cancer.

FUNDING

No financial conflicts of interest.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA: Cancer journal for clinicians* 2011; 61:69-90.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 incidence and mortality web-based report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. 2015. Available at: www.cdc.gov/uscs.
3. American Cancer Society. Cancer Facts & Figures. American Cancer Society 2009.
4. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [internet]. International Agency for Research on Cancer, Lyon. globocan.iarc.fr. 2013.
5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *European Journal of Cancer* 2013;49:1374-403.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA: A Cancer Journal for Clinicians* 2007;57:43-66.
7. Cox LS, Africano NL, Tercyak KP, Taylor KL. Nicotine dependence treatment for patients with cancer. *Cancer* 2003;98:632-44.
8. Centers for Disease Control and Prevention (CDC). State-specific prevalence of current cigarette smoking among adults and secondhand smoke rules and policies in homes and workplaces--United States, 2005. *MMWR: Morbidity and Mortality Weekly Report* 2006;55:1148.
9. Cooley ME, Sipples RL, Murphy M, Sarna L. Smoking cessation and lung cancer: oncology nurses can make a difference. In: *Seminars in Oncology Nursing* 2008; 24:16-26. WB Saunders.
10. Dresler CM. Is it more important to quit smoking than which chemotherapy is used? *Lung Cancer* 2003;39:119-24.
11. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. *Lung Cancer* 2004;44:287-93.
12. Cox LS, Africano NL, Tercyak KP, Taylor KL. Nicotine dependence treatment for patients with cancer. *Cancer* 2003;98:632-44.
13. Nia PS, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of smoking status in operated non-small cell lung cancer. *Lung Cancer* 2005;47:351-9.
14. Dresler CM, Bailey M, Roper CR, Patterson GA, Cooper JD. Smoking cessation and lung cancer resection. *CHEST Journal* 1996;110:1199-202.
15. Gritz ER, Nisenbaum R, Elashoff RE, Holmes EC. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. *Cancer Causes & Control* 1991;2:105-12.
16. Sarna L. Smoking behaviors of women after diagnosis with lung cancer. *Image: The Journal of Nursing Scholarship* 1995;27:35-41.
17. Alberg AJ, Samet JM. Epidemiology of lung cancer. *Chest Journal* 2003;123(suppl 1):21S-49S.
18. Official Statement of the ATS Board of Directors. Cigarette smoking and health. *Am J Respir Crit Care Med* 1996;153:861-5.
19. Balint B, Donnelly LE, Hanazawa T, Kharitonov SA, Barnes PJ. Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke. *Thorax* 2001;56:456-61.
20. Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. *Mutation Research/Reviews in Mutation Research* 2008;659:221-31.
21. Yoshino I, Maehara Y. Impact of smoking status on the biologi-

- cal behavior of lung cancer. *Surgery Today* 2007;37:725-34.
22. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. *Nature Medicine* 2001;7:833-9.
 23. Cooke JP. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. *Life Sciences* 2007;80:2347-51.
 24. U.S. Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000.
 25. Stewart AL, King AC, Killen JD, Ritter PL. Does smoking cessation improve health-related quality-of-life?. *Annals of Behavioral Medicine* 1995;17:331-8.
 26. Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. *Chest Journal* 2004;126:1733-41.
 27. Baser S, Shannon VR, Eapen GA, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. *CHEST Journal* 2006;130:1784-90.
 28. Leon M, Dresler C, Straif K, Baan R, Secretan B. Reversal of risk after quitting smoking. *Cancer Epidemiology Biomarkers & Prevention* 2006;15(Supplement 12):B46-.
 29. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328(7455):1519.
 30. Zhou W, Heist RS, Liu G, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. *Lung Cancer* 2006;53:375-80.
 31. Chen J, Qi Y, Wampfler JA, et al. Effect of cigarette smoking on quality of life in small cell lung cancer patients. *European Journal of Cancer* 2012;48:1593-601.
 32. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* 2010 Jan 22;340.
 33. Dresler CM, Bailey M, Roper CR, Patterson GA, Cooper JD. Smoking cessation and lung cancer resection. *Chest Journal* 1996;110:1199-202.
 34. Møller AM, Villebro N, Pedersen T, Tønnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *The Lancet* 2002;359:114-7.
 35. Yildizeli B, Fadel E, Mussot S, Fabre D, Chataigner O, Darteville PG. Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer. *European Journal of Cardio-Thoracic Surgery* 2007;31:95-102.
 36. Suzuki M, Otsuji M, Baba M, Saitoh Y. Bronchopleural fistula after lung cancer surgery: multivariate analysis of risk factors. *Journal of Cardiovascular Surgery* 2002;43:263.
 37. Harpole DH, DeCamp MM, Daley J, et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. *The Journal of Thoracic and Cardiovascular Surgery* 1999;117:969-79.
 38. Wright CD, Gaissert HA, Grab JD, O'Brien SM, Peterson ED, Allen MS. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. *The Annals of Thoracic Surgery* 2008;85:1857-65.
 39. Schwilk B, Bothner U, Schraac S, Georgieff M. Perioperative respiratory events in smokers and nonsmokers undergoing general anaesthesia. *Acta Anaesthesiologica Scandinavica* 1997;41:348-55.
 40. Barrera R, Shi W, Amar D, et al. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. *Chest Journal* 2005;127:1977-83.
 41. Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. *Chest Journal* 2001;120:705-10.
 42. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. *The Annals of Thoracic Surgery* 2009;88:362-71.
 43. Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. *Annals of Surgical Oncology* 2012;19:1430-8.
 44. Hoffmann DH. The changing cigarette, 1950-1995. *Journal of Toxicology and Environmental Health Part A* 1997;50:307-64.
 45. Vaporciyan AA, Merriman KW, Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. *The Annals of Thoracic Surgery* 2002;73:420-6.
 46. Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. *Lung Cancer* 2005; 47:165-72.
 47. Sawabata N, Miyoshi S, Matsumura A, et al. Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma. *General Thoracic and Cardiovascular Surgery*. 2007; 55:420-4.
 48. Martínez-García E, Irigoyen M, Ansó E, Martínez-Irujo JJ, Rouzaut A. Recurrent exposure to nicotine differentiates human bronchial epithelial cells via epidermal growth factor receptor activation. *Toxicology and Applied Pharmacology* 2008; 228:334-42.
 49. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. *Clinical Pharmacokinetics* 1999; 36:425-38.
 50. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. *Journal of Clinical Oncology* 2007; 25:3055-60.
 51. Kroon LA. Drug interactions with smoking. *American Journal of Health-System Pharmacy* 2007;64:1917-21.
 52. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123-32.
 53. O'Malley M, King AN, Conte M, Ellingrod VL, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. *Journal of Thoracic Oncology*

- 2014;9:917-26.
54. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. *Journal of the National Cancer Institute* 2001;93:1879-85.
 55. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. *Cancer* 1998;82:842-50.
 56. Sarihan S, Ercan I, Saran A, Çetintas SK, Akalin H, Engin K. Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy. *Cancer Detection and Prevention* 2005;29:181-8.
 57. Chen J, Jiang R, Garces YI, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. *Lung Cancer* 2010;67:221-6.
 58. Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. *Journal of Clinical Oncology* 2003;21:1544-9.
 59. Cataldo JK. Clinical implications of smoking and aging: breaking through the barriers. *Journal of Gerontological Nursing* 2007;33:32-41.
 60. Horner MJ, Ries LA, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. 2009, pp. 545-76.
 61. Cancer Research UK. CancerStats. 2007. <http://info.cancer-researchuk.org/cancerstats>
 62. Shiels MS, Gibson T, Sampson J, et al. Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. *Journal of Clinical Oncology* 2014;32:3989-95.
 63. Boyle JM, Tandberg DJ, Chino JP, D'Amico TA, Ready NE, Kelsey CR. Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis. *Cancer* 2015;121:598-604.
 64. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. *Annals of Internal Medicine* 1993;119:383-90.
 65. Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. *Annals of Oncology* 2013;24:2699-704.
 66. National Comprehensive Cancer Network. NCCN guidelines version 3. 2012 Non-Small Cell Lung Cancer. Fort Washington, NCCN. 2012.
 67. de Moor JS, Elder K, Emmons KM. Smoking prevention and cessation interventions for cancer survivors. In: *Seminars in Oncology Nursing* 2008; 24:180-92. WB Saunders.
 68. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy. *Chest Journal* 2007;132:355s-67s.
 69. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Le Marchand L. Smoking history and survival among lung cancer patients. *Cancer Causes & Control* 1990;1:155-63.
 70. Silverman S, Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. *The Journal of the American Dental Association* 1983;106:33-5.
 71. Stevens MH, Gardner JW, Parkin JL, Johnson LP. Head and neck cancer survival and life-style change. *Archives of Otolaryngology* 1983;109:746-9.
 72. Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. *British journal of cancer* 1998;78:409.
 73. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. *Journal of the National Cancer Institute* 1997;89:1782-8.
 74. Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. *Journal of Clinical Oncology* 1999;17:2086-91.
 75. Sridhar KS, Raub WA. Present and past smoking history and other predisposing factors in 100 lung cancer patients. *Chest Journal* 1992;101:19-25.
 76. Cooley ME, Emmons KM, Haddad R, et al. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. *Cancer* 2011;117:2961-9.
 77. Schnoll RA, Rothman RL, Lerman C, et al. Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment. *Head & Neck* 2004;26:278-86.
 78. Walker MS, Vidrine DJ, Gritz ER, et al. Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. *Cancer Epidemiology Biomarkers & Prevention*. 2006;15:2370-7.
 79. Cooley ME, Wang Q, Johnson BE, et al. Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. *Lung Cancer* 2012;76:144-9.
 80. Gilpin EA, White MM, Farkas AJ, Pierce JP. Home smoking restrictions: which smokers have them and how they are associated with smoking behavior. *Nicotine & Tobacco Research* 1999;1:153-62.
 81. Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. *Journal of Thoracic Oncology* (Official publication of the International Association for the Study of Lung Cancer) 2013;8:543.
 82. Cummings KM, Dresler CM, Field JK, et al. E-cigarettes and cancer patients. *Journal of Thoracic Oncology* (Official publication of the International Association for the Study of Lung Cancer) 2014;9:438-41.